T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-
Hodgkin's lymphoma (T-NHL) are the most important aggressive neoplastic disorders of lymphocytes committed to the T-cell lineage. Over the past decades, survival rates of the patients have remarkably improved, because of advances in chemotherapeutic protocols; however, relapse is frequently observed, and these patients eventually present poor clinical outcome. Therefore, novel biological relevant treatments are needed to be developed, either alone or in combination with conventional chemotherapy.
Initially identified from the physiological function of the normal hematopoietic cells, multiple signal transduction pathways are aberrantly expressed in their tumor counterparts and closely related to disease progression. Accumulating evidences indicate that improper activation of these networks are key events in the pathogenesis of T-cell malignancies, making intermediates in these pathways, excellent candidates for molecular targeting. This review discusses what these dysregulations have contributed to the T-cell tumorigenesis, and how they provide insights to the development of new targeted therapies.
Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway has a critical function in cell proliferation, cell-cycle progression, and apoptosis. 1 Stimulated by growth factors, PI3K catalyzes the production of phosphatidylinositol 3,4,5 trisphosphate (PIP3), thereby activates a number of downstream targets, including Akt. A major negative regulator of the Akt pathway is the lipid phosphatase PTEN (phosphatase and tensin deleted on chromosome 10), which removes the 3-phosphate from PIP3, thus down-modulating Akt signaling. 2, 3 An important Akt target that is relevant in tumorigenesis and drug resistance is mTOR. Activated mTOR supports tumor cells by stimulating the synthesis of proteins necessary for cell growth, survival, angiogenesis, nutrient uptake, and metabolism. 4 During normal T-cell development, PI3K/Akt promote the differentiation and the transition of double-negative thymocytes to the double-positive stage, as well as the survival of the double-positive thymocytes, following the activation by pre-TCR (T-cell antigen receptor) signals. 5 Constitutive activation of Akt pathway because of mutational loss of PTEN is a common feature of T-ALL. It has been reported that, in T-ALL, Akt signaling is up-regulated by transcriptional repression of PTEN. 6 Recently, another study has highlighted that PTEN posttranslational inactivation through phosphorylation and oxidation could result in Akt activation in T-ALL. 7 As a result, leukemic cells isolated from patients with T-ALL at the time of diagnosis frequently present hyperactivation of Akt pathway. 7 In T-NHL, anaplastic lymphoma kinase (ALK) overexpression, observed in anaplastic large-cell lymphoma (ALCL) carrying chromosomal translocation t(2;5)(p23;q35) or variant translocations, favors Akt phosphorylation and consequent activation. Accordingly, the main downstream proteins, such as mTOR, p70 ribosomal S6 kinase (p70S6 K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), are highly phosphorylated in ALK þ ALCL cell lines and tumors. 8 In adult T-cell leukemia/ lymphoma (ATLL), human T-cell leukemia virus type I (HTLV-I) encodes an oncoprotein, Tax, which up-regulates phosphorylated Akt, contributing to the activation of Akt cascade and onset of ATLL.
9,10 NK/T-cell lymphoma (NKTL) is strongly associated with latent Epstein-Barr virus (EBV) infection. Latent membrane protein 1 (LMP1), the EBV oncoprotein, could initiate the Akt activation for tumor cell survival. 11 High level of phosphorylated Akt is also detected in cutaneous T-cell lymphoma (CTCL) and T-cell large granular lymphocytic leukemia (T-LGL). 12, 13 Novel therapeutics inhibiting the PI3K/Akt/mTOR axis has become attractive candidates for treatment of T-cell malignancies. mTOR inhibitor rapamycin shows promising effects in preclinical models. It displays a potent anti-leukemic effect in the T-ALL cell line Jurkat by inhibition of cell proliferation through G1 cell-cycle arrest and the suppression of telomerase activity.
14 In addition to cell-cycle regulation, rapamycin is able to stimulate apoptosis in primary leukemic blasts of childhood T-ALL. 15 In ALK þ ALCL, rapamycin inhibits phosphorylation of mTOR signaling proteins, markedly decreases cell proliferation and increases apoptosis. 8, 16 In CTCL, rapamycin suppresses cell proliferation but shows little effect on the apoptotic rate. 13 Importantly, rapamycin overcomes the drug resistance conferred by Akt pathway. It augments the glucocorticoid sensitivity of resistant T-ALL cell line CEM, an effect that is shown to be associated with decreased Mcl-1 level. 17 Rapamycin also promotes doxorubicin-induced apoptosis in childhood T-ALL blasts even in non-responder samples. 15 However, mTOR inhibitors could hyperactivate Akt because of the existence of feedback loops between mTOR, PI3K, and Akt. 18, 19 Recently, dual PI3K/mTOR inhibitors have been synthesized, including PI-103, a small molecule of the pyridofuropyrimidine class. 20 As PI-103 targets both class IA PI3K and mTOR, it does not lead to Akt activation, which is seen when only mTOR is targeted by inhibitors. PI-103 possesses strong cytotoxic activity against T-ALL cell lines and lymphoblasts derived from T-ALL patients, accompanied by dephosphorylation of Akt and its downstream target glycogen synthase kinase-3b (GSK3b). Also, mTOR downstream targets, p70S6 K and 4E-BP1, are dephosphorylated in response to PI-103. Of note, PI-103 is more potent than inhibitors that are selective only for PI3K (LY294002) or for mTOR (rapamycin). 21 In other situations, longitudinal inhibition of PI3K/Akt/mTOR axis using combined treatment also represents a promising strategy. In ATLL, when rapamycin is combined with PI3K inhibitor LY294002, rapamycin-induced phosphorylation of Akt is blocked, and the ability of rapamycin to induce growth arrest of HTLV-I-infected T cells and suppress the phosphorylated p70S6 K and 4E-BP1 proteins is potentiated. 10 Akt inhibitors may also serve as efficient therapeutic agents. Perifosine is an Akt inhibitor with significant anti-neoplastic effects in human tumor cell lines and is currently being tested in phase II clinical trials for treatment of major human cancers. Perifosine induces apoptosis in chemoresistant CEM cells, characterized by caspase activation, Bid cleavage, and cytochrome c release from mitochondria. 22 Perifosine combined with etoposide induces cell death in a synergistic manner in Jurkat cells, because of the inactivation of Akt and subsequent down-regulation of anti-apoptotic Bcl-xL and transcription factor FOXO expression. 23 Novel Akt inhibitor (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) leads to rapid cell death of T-ALL cell lines Jurkat, CEM, and MOLT-4, as well as primary patient samples. Effective as a single agent, A443654 synergized with etoposide either co-administered or pretreated with etoposide followed by A443654. 24 Other molecular inhibitors could be useful for achieving disease control by targeting the Akt pathway. Serine/threonine kinase inhibitor enzastaurin displays pro-apoptotic properties against a spectrum of malignancies and is currently being investigated in clinical trials on solid tumors and relapsed/ refractory B-cell NHL. Enzastaurin induces apoptosis in the CTCL cell lines Hut-78 and HH, by down-regulating Akt, GSK3b, and p70S6K. 25 Heat-shock protein 90 inhibitor geldanamycin (GA) and its derivative, 17-allylamino-17-demethoxygeldanamycin (17-AAG), exhibit anti-tumor activity and promote apoptosis in EBV þ NKTL cell lines, Hank-1 and NK-YS, via decreasing Akt and phosphorylated Akt expression, and consequently activating pro-apoptotic apoptosis signalregulating kinase 1.
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Natural compounds with Akt inhibitory capacities may have potential clinical implications. Resveratrol, a well-known component of the skin of grapes, is present in high concentrations in red wine. Resveratrol increases apoptosis in MOLT-4 cells by inhibiting Akt pathway. 26 Genistein, a natural isoflavonoid found in soy products, inhibits cell growth and induces apoptosis of ALK þ ALCL cell lines, SUDHL-1 and Karpas299, with concurrent decrease of Akt levels and subsequent down-regulation of Akt activity. 27 Curcumin (diferuloylmethane) is a naturally occurring yellow pigment, isolated from the rhizomes of the plant Curcuma longa that has traditionally been used in the treatment of injury and inflammation. Curcumin suppresses constitutively activated Akt, transcription factor FOXO and GSK3 in T cells, leading to the inhibition of proliferation and induction of caspase-dependent apoptosis in T-ALL cell lines. 28 
Notch pathway
Notch signaling is a key regulator of thymic maturation and peripheral T-cell proliferation. 29 The Notch family consists of four conserved transmembrane receptors, termed Notch 1-4 that share a high degree of structural similarity. Activation of Notch signaling is initiated through interaction of the Notch extracellular domain with a Delta-Serrate-Lag2 ligand (Deltalike 1, 3 and 4; and Jagged 1 and 2) located on the surface of an adjacent cell. This interaction allows ligand-mediated proteolytic cleavage of the receptor with the consequent release and translocation of intracellular domain to the nucleus, in which it executes Notch functions by turning on the transcription of target genes. 30 Notch1 is expressed in the bone marrow precursors and necessary for T-cell specification in the thymus. It up-regulates interleukin (IL)-7 receptor a expression, promoting the survival and proliferation of double-negative progenitors. 31 Thereafter, Notch1 signaling, along with the pre-TCR signaling, converges on the PI3K/Akt pathway during the double-negative to double-positive transition. In the periphery, Notch3 signaling involves in differentiation of T-regulatory cells and T-helper cells. 29 Dysregulation of the Notch1 pathway has emerged as an important genetic component in T-ALL. Notch1 was first discovered through its involvement in chromosomal translocation t(7;9)(q34;q34) in T-ALL and was subsequently proved essential for T-cell leukemogenesis. 32 Mice reconstituted with hematopoietic progenitor cells expressing activated Notch1 allele develop T-cell leukemia, 33 whereas blockade of Notch pathway suppresses the growth and survival of Notch1-transformed T-ALL cells. 34 Gain-of-function Notch1 mutations have been reported in 450% of T-ALL patients, confirming the pathogenetic role of Notch1 activation on T-ALL. 35 Lymphomas generated by thymic irradiation of mice often exhibit an increase in Notch1 expression. 36 In the clinical part, Notch1 expression is observed in primary tumor samples of nodal and cutaneous ALCL. 37, 38 Interaction between Notch1 on ALCL cells and its ligand Jagged1 accelerates tumor cell growth and inhibits apoptosis. Interestingly, Jagged1 is expressed in both malignant and bystander cells co-localizing with Notch1-positive tumor cells. Notch1 signaling may therefore be activated in tumor cells by Jagged1 through homotypic or heterotypic cell-cell interactions, and these interactions might contribute to lymphomagenesis. 37 Other members of the Notch family have also been implicated in T-cell malignancies. g-radiation-induced thymic lymphomas in mice often exhibit increased levels of Notch1 expression, but a clearly reduced Notch2 expression, suggesting the involvement of Notch2 inactivation in T-NHL. 36 Transgenic mice expressing the constitutively active intracellular domain of Notch3 show an increased number of thymocytes in thymus, particularly late double-negative cells, and subsequently develop T-cell leukemia/lymphoma. The tumors presents features of immature thymocytes, including expression of pTa, a potent signaling complex provoking thymocyte survival, proliferation, and activation. 39 The Notch ligand Delta-like 4 has a recognized function during both physiologic and tumor angiogenesis, as it contributes to regulate Notch activity in endothelial cells. The escape of human T-ALL cells from dormancy is associated with Delta-like 4 expression in the tumor microenvironment and increases Notch3 signaling in tumor cells. Neutralization of Delta-like 4 greatly reduces endothelial cellsmediated activation of Notch3 signaling in T-ALL cells and blocks tumorigenesis. 40 Notch4 expression is found in human bone marrow cells and in both CD34 þ and CD34À populations. Notch4-intracellular domain-transduced cord cells transplanted mice exhibits significantly higher levels of engraftment of immature T-cell population, whereas B-cell development is blocked. These results indicate that activation of Notch4 results in enhanced stem cell activity, reduced differentiation, and altered lymphoid development. 41 The identification of Notch activation in T-ALL and T-NHL has brought much interest in inhibiting Notch signaling as therapeutic target in these diseases. g-secretase inhibitors (GSIs), which mediate the proteolytic cleavage required for Notch activation, would appear to be ideal agents for achieving this goal. However, most T-ALL cell lines with Notch1 mutations fail to respond to GSI therapy. A recent report has identified loss of PTEN as a critical event leading to GSI resistance to Notch inhibition.
6 Notch1 down-regulates PTEN by HES1, resulting in the up-regulation of Akt pathway. PTEN-null/GSI resistant T-ALL cells switch their oncogene addiction from Notch1 to Akt and are highly sensitive to Akt pathway inhibitors. 42 Murine model study confirmed that T-ALL cell growth is suppressed in a highly synergistic manner by simultaneous treatment with the GSI and mTOR inhibitor rapamycin. 43 These results facilitate the development of molecular therapies targeting both Notch1 and Akt for the treatment of T-ALL.
Notch regulates cell-cycle progression in T cells and cyclin D3 is a direct target of Notch. Expression of cyclin D3, together with their catalytic partners cyclin-dependent kinase (CDK) 4 and CDK6, rescue T-ALL cell lines DND-41, HPB-ALL, and T-ALL1 from GSI-induced G1 arrest. Importantly, cyclin D3 and CDK4 are highly overexpressed in Notch-dependent T-cell lymphomas, justifying the combined use of cell-cycle inhibitors and GSI in treating T-cell malignancies. 44 Janus kinase/signal transducer and activator of transcription pathway Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is responsible for a wide range of actions induced by cytokines. Members of the JAKs family, JAK1, JAK2, JAK3, and TYK2, are cytoplasmic protein tyrosine kinases for the initial steps of cytokine signaling. 45 STATs (STAT1-6) are phosphorylated on tyrosine residues via JAK kinases, then dimerize, translocate to the nucleus and bind DNA, initiating the transcription of target genes. STAT proteins mediate cell growth, differentiation, apoptosis, transformation, and other fundamental cell functions. 46 STAT5 is required for bone marrow progenitor cell development and mediates doublenegative thymocyte survival. Peripheral T cells require both STAT3 and STAT5 for maintenance and differentiation: STAT5 is indispensable in T-regulatory cells and CD8 þ T cells, whereas STAT3 is critical for T-helper 17 cells. 47 In T-ALL, a TEL-JAK2 fusion gene was first described in a childhood T-ALL patient with chromosomal translocation t(9;12)(p24;p13). 48 It activates STAT5, and causes lethal myeloand T-cell lymphoproliferative disorder in murine bone marrow transplant models of leukemia. 49 More recently, JAK1 mutations have been observed in 18.4% of adult cases of T-ALL and associated with advanced age at diagnosis, poor response to therapy, and overall prognosis. Three mutations studied promote JAK1 gain of function and confer IL-3-independent growth in Ba/F3 cells and/or IL-9-independent resistance to dexamethasoneinduced apoptosis in T-cell lymphoma BW5147 cells. 50 Constitutive activation of JAK/STAT pathway has also been reported in T-NHL. JAK2 involvement is suggested to be of oncogenic importance in T-NHL, when PCM1-JAK2 fusion gene was first characterized in a lymphoblastic T-cell lymphoma patient with chromosome translocation t(8;9)(p22;p24). 51 Despite the rarity of activating JAK2 mutations, phosphorylated JAK2 is frequently detected in peripheral T-cell lymphoma (PTCL), along with its downstream effectors phosphorylated STAT3 and STAT5. 52 Moreover, by microarray, PTCL unspecified could be separated into three molecular subgroups, one of which is mainly defined by overexpression of genes involved in the JAK/STAT pathway. 53 In ALCL, activated JAK2 constitutes a pro-proliferative, anti-apoptotic signal. 54 NPM-ALK expression promotes cell survival by inducing expression of the antiapoptotic genes, Bcl-xL and survivin, largely mediated by STAT3.
55 JAK3, as well as STAT3 and STAT5, are hyperactivated in both HTLV-I-transformed T-cell lines and lymphocytes isolated from HTLV-I-infected patients. 56 T-LGL cells also display high levels of activated STAT3. 57 In CTCL, STAT3 expression protects tumor cells against apoptosis, 58 and STAT5 expression may be one mechanism that contributes to the cellular transformation of T cells in sezary syndrome (SS). 59 Dysregulated JAK/STAT function in T-cell malignancies points to this pathway as a target for the development of novel drugs. Two small-molecule, quinazoline-type tyrosine kinase inhibitors designated WHI-P131 (4-(4 0 -hydroxyphenyl) amino-6,7-dimethoxyquinazoline) and WHI-P154 (4-[(3 0 -bromo-4 0 -hydroxyphenyl) amino]-6,7-dimethoxyquinazoline) directly inhibit enzymatic activity of NPM/ALK and induce apoptosis in ALCL cells through inhibition of phosphorylation of STAT3. 60 AG-490 is a member of the tyrphostin family of tyrosine kinase inhibitors. It potently suppresses JAK2, JAK3 activity, and phosphorylation of STAT1, 3, 5a, and 5b. 61 Treatment of T-LGL with AG-490 induces apoptosis with a corresponding decrease in STAT DNA-binding activity and Mcl-1 down-regulation. 62 In SS, AG-490 inhibits STAT3 activation, STAT3 DNA binding, IL-2Ra mRNA and protein expression, and triggers apoptosis in tumor cells. 63 Natural products also exhibit inhibitory effect on JAK/STAT pathway. Treatment with curcumin could inhibit JAK/STAT phosphorylation, resulting in the induction of growth arrest and apoptosis in HTLV-I-transformed human T-cell lines MT-2 and HuT-102. 64 Cucurbitacin I is a member of the cucurbitacin family compounds that are isolated from various plant families such as the Cucurbitaceae and Cruciferae and have been used as folk medicines in China and India. As a specific JAK/STAT inhibitor, Cucurbitacin I selectively decreases STAT3 expression, and induces apoptosis in both the SS-derived cell line Seax and freshly isolated SS cells. 65 Avicin D belongs to a family of natural triterpenoid saponins derived from the Cactus plant Acacia victoriae found in Australia's deserts. Induction of tumor T-cell apoptosis, inhibition of STAT3 activation, and downregulation of Bcl-2 and survivin underlie the therapeutic potential of avicin D in patients with SS. 66 
Targeted therapy in T-cell malignancies W-L Zhao
Dysregulation of STAT activity has a function in histone deacetylase inhibitor vorinostat resistance in CTCL, and strategies that block this pathway may improve vorinostat response. Persistent activation of STAT1, 3, and 5 correlate with resistance to vorinostat in CTCL cell lines. Simultaneous treatment with a pan-JAK inhibitor resulted in synergistic anti-proliferative effect and down-regulation of the expression of anti-apoptotic genes Bcl-2, Bcl-xL, Mcl-1, and survivin. 67 Nuclear factor-jB pathway Nuclear factor (NF)-kB is a major factor of malignant T-cell transformation, drug resistance, and apoptosis. NF-kB family comprises five members: p65 (RelA), RelB, c-Rel, p50 (NF-kB1), and p52 (NF-kB2). These proteins form various NF-kB homoand heterodimers and are held captive in the cytoplasm by specific inhibitors known as the inhibitor of kB (IkB). On activation, the IkB kinases (IKKs) complex phosphorylates IkB and causes its degradation, allowing NF-kB to translocate from its inactive cytoplasmic location into the nucleus and initiate the transcriptional activation of target genes. 68 p65, c-Rel, and p50 are all expressed in double-positive and in single-positive thymocytes. 69 NF-kB has an important function in negative and positive selection during T-cell development in the thymus. 70 Moreover, TCR-induced signals to activate NF-kB are essential for mature T-cell activation. 71 Activation of p50 homodimers and p50/p65 heterodimers are detected in childhood T-ALL. 72 Recent study revealed a novel function of RelB in stromal cells that promote T-cell leukemogenesis. Actually, RelB is required in the stromal compartment to accelerate leukemia onset and increase disease severity in the TEL-JAK2 transgenic murine model of T-ALL. 73 As for T-NHL, HTLV-I-encoded Tax oncoprotein induces NF-kB activation, which is involved in the proliferation and activation of primary ATLL cells. Marked NF-kB activity is noted in the primary cells of patients with acute disease, but little activity in the cells of chronic patients. 74 During EBV infection, LMP1 induces the expression of early growth response gene-1 (Egr-1) via NF-kB. Egr-1 is required for LMP1-induced tumor cell survival and drug resistance. Similar relationships among EBV infection, Egr-1 and drug resistance are also observed in tissues samples of patients with PTCL unspecified. 75 NF-kB is constitutively activated in CTCL cell lines Hut-78, MyLa, and Seax and in peripheral blood lymphocytes from SS patients presenting a high ratio of tumor cells, with evidence of p50 and p65 in DNA-linked complexes. 76 Targeting NF-kB thus provides an attractive strategy for cancer therapy. Proteasome inhibitor bortezomib (Velcade, PS-341) controls NF-kB activation by proteasome-mediated degradation of IkBa. In vitro, bortezomib inhibits cell proliferation and induces apoptosis in fresh ATLL cells, HTLV-I-transformed and HTLV-I-negative malignant T cells. Combination of bortezomib and doxorubicin or etoposide resulted in an additive growth inhibition. In HTLV-I-negative malignant cells, bortezomib treatment mainly down-regulates the anti-apoptotic XIAP and results in caspase-dependent apoptosis. In HTLV-I-transformed cells, the inhibition of the proteasomal degradation of Tax by bortezomib likely explains the relative protection of HTLV-Iinfected cells against caspase-dependent apoptosis. Bortezomib treatment stabilizes IkB and selectively inhibits p65 DNAbinding NF-kB complexes. 77 In vivo, bortezomib is well tolerated and has significant single-agent activity in previously pretreated patients with CTCL. 76 Bortezomib combined with CHOP chemotherapy has recently been applied as first-line therapy in 13 patients with advanced, aggressive T-cell lymphoma. The overall complete remission rate in all patients was 61.5%. Bortezomib plus CHOP chemotherapy constitutes a safe and active regimen. 78 Other NF-kB inhibitors might also be beneficial, however, their therapeutic evidence has not yet been fully clarified. Hsp90 inhibitor GA leads to IKK autophagic degradation and NF-kB inhibition, triggering apoptosis of HTLV-transformed T cells and ATLL-derived cell lines. 79 Dehydroxymethylepoxyquinomicin inhibited tumor necrosis factor-a (TNF-a)-induced nuclear accumulation of p65 and transcriptional activity of NF-kB in Jurkat cells. 80 TNF-a function inhibitors, conophylline, a vinca alkaloid isolated from the plant Ervatamia microphylla, is found to inhibit TNF-a-induced NF-kB activation, as well as phosphorylation and degradation of IkBa, in Jurkat cells. 81 
Calcineurin/NF of activated T cells pathway
Calcineurin/nuclear factor of activated T (NFAT) signaling is an essential pathway implicated in differentiation, activation, and elimination of lymphocytes. 82 Caleincurin is composed of a catalytic (CnA) and a regulatory (CnB) subunit. Increase in intracellular calcium results in calcium-dependent binding of calmodulin to calcineurin, thus relieving the inhibitory activity of the autoinhibitory domain on CnA and leading to the dephosphorylation, nuclear translocation, and consequent activation of calcineurin substrates NFAT. NFAT comprises five structurally related members: NFATc1, c2, c3, c4, and NFAT5. In the T-cell lineage, calcineurin is important for pre-TCR signaling and positive selection of thymic T-cell. Mice with conditional deletion of the CnB1 gene early in thymocytes development exhibit an 80% decrease in thymic cellularity, perturbed pre-TCR signaling and the complete absence of TCR-mediated positive selection of mature T cells. 83 NFATc1, c2, and c3 are the members expressed in the T lymphocytes.
Transduction of T-ALL cells with a calcium independent, constitutively activated mutant of calcineurin is found to enhance their aggressiveness and to favor leukemia progression in murine T-ALL models, indicating that calcineurin activation contributes to the pathogenesis of T-ALL. 82 An immunohistological screening of NFATc1 in a large series of lymphomas showed that NFATc1 is expressed in almost all categories of T-NHL studied. 84 Also, nuclear localization of NFATc1 or dephosphorylation of both NFATc1 and NFATc2 are revealed by western blot in PTCL. 85 In contrast, NFATc3 expression is repressed in mice T-cell lymphomas induced by the murine lymphomagenic retrovirus SL3-3. Furthermore, NFATc3-deficient mice infected with SL3-3 develop T-cell lymphomas faster and with higher frequencies than wild-type mice or NFATc2-deficient mice, suggesting that NFATc3 could act as a tumor suppressor for T-cell malignancies. 86 Calcineurin/NFAT targeting by specific inhibitors is of therapeutic value in the treatment of T-cell malignancies. Interestingly, cyclosporine (CsA) and FK506 are well-characterized immunosuppressive agents that exert an inhibitory effect on calcineurin to inhibit its ability to dephosphorylate NFAT. NFAT activation in cell lines derived from T-ALL could be suppressed in response to CsA or FK506 treatment. In intracellular Notch1-and TEL-JAK2-induced murine T-ALL models, in vivo inhibition of NFAT pathway by CsA or FK506 resulted in apoptosis of leukemic cells, rapid tumor clearance, and substantially prolonged mouse survival. 85 Although their efficiency is verified preclinically, 85 the side effects may compromise the usefulness of CsA and FK506 in treating T-ALL/T-NHL. It is therefore of particular interest to study the anti-tumor effect of derivatives of CsA and FK506, like L-732531 (an analog of FK506) 87 and ISATX247 (an analog of CsA), 88 which show comparable or even higher efficiency toward calcineurin inhibition with reduced toxicity.
Mitogen-activated protein kinase pathway
Mitogen-activated protein kinase (MAPK) cascade is another important controller in cell proliferation, differentiation, or survival. In mammalian cells, three MAPK families have been characterized: extracellular signal-regulated kinase (ERK), which preferentially regulates cell growth and differentiation, as well as the c-Jun N-terminal kinase (JNK) and p38-MAPK cascades, which function mainly in stress responses like inflammation and apoptosis. 89 In normal thymocytes, TCR controls positive selection by modulating ERK activity, 90 whereas the p38-MAPK pathway regulates negative selection. 91 The activation of the JNK pathway is relevant in peripheral T cells. 92 The involvement of MAPKs in T-ALL is not clearly established. The TAL1 protein, commonly overexpressed because of recurrent chromosomal rearrangements in T-ALL, is phosphorylated by ERK1 in Jurkat cells. 93 This modification has been suggested to positively regulate TAL1 transactivation potency and may therefore link ERK to T-ALL leukemogenesis. 94 JNK status correlates with the pro-apoptotic Bcl-2-interacting mediator of cell death (Bim) level and in turn controls the sensitivity of T-ALL cells to chemotherapeutic agents. Constitutive activation of JNK pathway in T-ALL cell line Sup-T1 promotes phosphorylation and degradation of Bim, subsequently confers resistance of Sup-T1 cells to etoposide-induced apoptosis. Pretreatment of Sup-T1 cells with a specific JNK inhibitor, SP600125, increased the Bim level and re-sensitized the cells to etoposide. 95 In T-NHL, expression of NPM-ALK results in ERK1/2 activation and transcriptional up-regulation of the activator protein 1 (AP-1) transcription factor JUNB. 96 Physically binding to NPM-ALK, JNK is highly activated in cultured and primary NPM-ALK þ ALCL cells. JNK increases AP-1 transcriptional activity and mediates c-JUN phosphorylation. Both ERK and JNK activation are associated with increased cell proliferation and G2/M cell-cycle arrest, indicating that MAPKs may contribute to oncogenesis in ALCL. 96 CTCL patients also express phosphorylated and total ERK, inducing aberrant AP-1 activation and JUNB expression. 97 Malignant CTCL T cells spontaneously produce the angiogenic protein, vascular endothelial growth factor, which is promoted, at least in part, by JNK activation. p38-MAPK is related to drug resistance, but varies according to different drugs. Treatment of CEM cells with the glucocorticoids activates p38-MAPK and then induces mRNA transcription and protein levels of Bim. Glucocorticoids-induced apoptosis is inhibited by pretreatment with a p38-MAPK inhibitor, SB203580, which also reduces Bim induction. 99 Conversely, 2-Chloro-2 0 -deoxyadenosine (CdA; cladribine) causes Jurkat cell death via apoptosis, and increases p38-MAPK phosphorylation. Inhibition of p38-MAPK has an enhancing effect on CdA-mediated cytotoxicity. Agents that inhibit p38-MAPK might therefore increase the effectiveness of CdA-based chemotherapy. 100 Pharmacologic modulation of MAPKs represents new investigational treatment options. Glutathione S-transferase (GST) P1-1 is an enzyme that displays anti-apoptotic activity. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol, the most effective GSTP1-1 inhibitor, exhibits strong cytotoxic activity in CEM cells, promoting the dissociation of the GSTP1-1 in a complex with JNK, triggering JNK activation and resulting in leukemia cell apoptosis.
101 LY293111 (2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-propoxy]-phenoxy] benzoic acid sodium salt) is a leukotriene B4 receptor antagonist, which is found to be safe and tolerable in Phase I clinical trials. It has potential therapeutic effects on ALCL cell lines, inhibiting proliferation of both ALK þ and ALK-ALCL cells and inducing G1/S cell-cycle arrest, accompanied by up-regulation of p27 and down-regulation of cyclin E. Treatment with LY293111 results in profound inhibition of phosphorylation of ERK1/2 and a concomitant increase in the phosphorylation of JNK. 102 Paeoniflorin, isolated from paeony root, has been used as an herbal medicine in China, Korea, and Japan for its anti-allergic, anti-inflammatory, and immuno-regulatory effects. It induces apoptosis in Jurkat cells mediated through the phosphorylation of all three MAPKs, ERK, JNK, and p38-MAPK. 103 Also, benzyl isothiocyanate, one of the compounds from cruciferous vegetables, could inhibit G2/M cell progression and induces apoptosis in Jurkat cells. Benzyl isothiocyanate activated JNK and p38-MAPK, but not ERK, at the concentration required for apoptosis induction. 104 
Cross talk between pathways
Malignant T cells show the alterations in multiple cellular signaling pathways, which are highly integrated networks (Figure 1) . Regulation of PTEN expression by Notch1 via HES1 mediates the up-regulation of Akt pathway. 6 Cytokines can also activate PI3K via JAK1. The downstream targets of Akt not only include mTOR, but also GSK3b, a NFAT kinase, 105 IKKs, which lead to NF-kB activation, as well as ASK1 (apoptosis signalregulating kinase-1) and Raf1 (v-Raf1 murine leukemia viral oncogene homolog-1), which up-regulate JNK, p38-MAPK and ERK, respectively.
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There is also evidence of a complex interplay between Notch and other signaling pathways. Murine tumors induced by activated forms of Notch3 have high levels of activated NFkB, 39 and recent data suggest that this is also true of human T-ALL associated with activated Notch1. 106 Notch may augment NFkB activity by stimulating IKKs activity. 107 Notch effectors HES1 and HES5 could associate with JAK2 and STAT3, and facilitate complex formation between JAK2 and STAT3, thus promoting STAT3 phosphorylation and activation. 108 Likewise, increased calcineurin/NFAT activity by Notch signaling involves downregulation of calcipressin (CSP1), an endogenous calcineurin inhibitor, through a HES1-dependent mechanism.
109 Notch1 suppresses the activity of JNK-interacting protein 1 (JIP1) in the JNK signaling pathway. Indeed, intracellular domain of Notch1 physically associated with the JNK-binding domain of JIP1 and thereby interfered with the interaction between JIP1 and JNK. 110 In addition, coordination mechanism has been proposed between MAPKs and other pathways, like JAK/STAT and calcineurin/NFAT. ERK targets include STAT1, 3, and 5a, 111, 112 activation of STAT3 can also be induced by JNK. p38-MAPK and JNK act as negative regulators of calcineurin/ NFAT pathway through rephosphorylating NFAT. 113 Therefore, it is possible that intermediates targeting single pathway may not prove ultimately successful, because of the crosstalk that occurs among these pathways. This phenomenon, which may lead to acquired resistance to single signal transduction inhibitors, needs to be anticipated as these targeted agents move from the laboratory to the clinic. For example, Loss of PTEN is associated with resistance to pharmacologic inhibition of Notch1 signaling by GSIs, demonstrating an important function for PI3K/Akt signaling in Notch1 mutant T-ALL. When GSIs are administered in combination with mTOR inhibitor rapamycin, T-ALL cell apoptosis is significantly improved. This suggests the need to simultaneously inhibit different pathways as a means to improve therapeutic efficacy, which represents a rational drug combination for treating in T-cell malignancies. In Jurkat cells, multi-kinase inhibitor sorafenib interacts synergistically with bortezomib to induce apoptosis, involving modulation of both Akt and JNK signaling cascades. 114 Bortezomib combined with vorinostat induces T-leukemia/lymphoma cells to undergo apoptosis in a synergistic manner, accompanied by inhibition of NF-kB, ERK, and AKT pathways, and activation of JNK and p38-MAPK. 115 Thus, in addition to drug combination, multi-targeted agent could be an excellent candidate. Particularly, natural products have inhibitory effect on tumor cells, by regulating multiple cellular signaling pathways. 116 Further clinical development of these agents seems warranted.
Conclusions
Malignant T cells are known to have alterations in multiple cellular signaling pathways, which open new avenues for targeted therapy. However, these therapeutic agents are largely in the preclinical stage. Because of the complexities in the communication between multiple signaling networks, in addition to the combination of specific inhibitors that target only one pathway, multi-targeted agents, including the natural products, should be considered to further improve the therapeutic efficiency of T-cell malignancies.
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The author declares no conflict of interest. Figure 1 Interactions between multiple cellular signaling pathways. Notch enhances the activity of IkB kinases (IKKs) to active the nuclear factor (NF)-kB pathway, while suppresses the activity of JNK-interacting protein 1 (JIP1) to inhibit the JNK pathway. Notch acts on HES, which negatively modulates the expression of calcineurin inhibitor calcipressin (CSP1) and phosphatidylinositol 3-kinase (PI3K) inhibitor phosphatase and tensin deleted on chromosome 10 (PTEN), but activates Janus kinase (JAK). Inhibition of PTEN and CSP1 results in, respectively, up-regulation of the calcineurin and Akt pathway. Akt inhibits downstream target glycogen synthase kinase-3b (GSK3b), a kinase of NFAT cells, but activates IkB kinases (IKKs), apoptosis signal-regulating kinase-1 (ASK1) and v-Raf1 murine leukemia viral oncogene homolog-1 (Raf1). ASK1 is involved in the activation of the JNK and p38-mitogen-activated protein kinases (p38-MAPK) pathway. Raf1 is responsible for activation of the ERK pathway. Moreover, JNK and ERK are activators of signal transducer and activator of transcription (STAT). JNK and p38-MAPK mediate NFAT rephosphorylation, resulting in NFAT inhibition.
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